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Objective: The endothelium-derived vasoconstrictor endothelin-1 is increased after
cardiopulmonary bypass in children with congenital heart defects. This study
determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb
extract containing phenolic compounds, prevents the postoperative increase of
endothelin-1. The relationship between endothelin-1 and the endothelium-derived
prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also inves-
tigated.
Methods: Twenty children with congenital heart defects and pulmonary hyperten-
sion were randomly assigned to group A (placebo control, n10) or B (200 mg/kg
Salvia miltiorrhiza intravenously after anesthesia induction and at the time of
rewarming, respectively; n 10) before cardiac surgery. Central venous blood
samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting
cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and
30 minutes (T5) and 24 hours (T6) after termination of cardiopulmonary bypass.
Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine
kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1 (stable metab-
olites of thromboxane A2 and prostaglandin I2) were measured.
Results: Malondialdehyde increased significantly at T1 in group A and remained
significantly higher than in group B thereafter (P  .05). Malondialdehyde in group
B did not significantly increase over time. At T5, plasma creatine kinase-MB,
thromboxane B2, and endothelin-1 in group B were lower than in group A (P 
.05); malondialdehyde correlated significantly with creatine kinase-MB (r  0.71,
P  .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin
F1/thromboxane B2 ratio (r  0.64, P  .0025).
Conclusion: Antioxidant therapy reduces myocardial damage and attenuates post-
operative vasoactive mediator imbalance.
Endothelial regulation of local vascular tone is mediated by a varietyof endothelium-derived relaxing and contracting factors such asnitric oxide (NO), prostaglandin (PG) I2, thromboxane (TX) A2, andendothelin (ET)-1.1 ET-1 is a potent vasoconstrictor known to re-duce myocardial contractility and contribute to the progression of theheart failure process.2,3 The plasma level of ET-1 increases during
cardiac operations requiring cardiopulmonary bypass (CPB).4-7 A high plasma ET-1
level during the early postoperative period has been associated with prolonged
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pharmacologic management, longer intensive care unit stay,
and complicated recovery.4,8
In children undergoing surgical correction of congenital
heart defects, the postoperative level of plasma ET-1 is
increased significantly in patients with concomitant pulmo-
nary hypertension compared with those without.6,7 Reduc-
ing the plasma ET-1 level with modified ultrafiltration has
been shown to reduce the incidence of postoperative pul-
monary hypertension in these patients, facilitating improved
postoperative recovery.9
Oxygen-free radicals (OFRs) have been reported to me-
diate coronary endothelial dysfunction in vitro10 and after
CPB in humans.11 A recent study has shown that significant
systemic production of free radicals occurs after initiation of
CPB and persists during early reperfusion.12 A link between
free radical generation and vasoactive mediator production
has been identified.13 Oxidative stress has been reported to
increase ET-1 synthesis in human coronary artery smooth
muscle cells.14 It is unknown, however, whether antioxidant
intervention can effectively reduce postoperative plasma
ET-1 formation, attenuate the imbalance of PGI2 and TXA2
production seen after operations with CPB,15,16 and im-
prove clinical outcomes in this clinical setting.
Salvia miltiorrhiza (SM), an herb extract containing phe-
nolic compounds such as salvianolic acid A (Figure 1), has
been shown to be a potent free-radical scavenger.17,18 We
applied SM injection (SMI), a novel approach to antioxidant
therapy, during cardiac surgery in patients with congenital
heart defects and pulmonary hypertension.
Patients and Methods
Patient Selection
Permission to conduct this study was given by the ethics commit-
tee of the Renmin Hospital, Wuhan, China. Twenty children (aged
2-15 years old) with mild pulmonary hypertension (mean pulmo-
nary pressure to mean systemic arterial pressure 0.31-0.43) sched-
uled for operative repair of congenital ventricular or atrial septum
defect (ventriculoseptal defect or atrial septic defect) were enrolled
in this double-blind randomized study. Primary assessment of
pulmonary hypertension was based on clinical, radiographic, and
echocardiographic evidence of high pulmonary flow. Patients’
absolute pulmonary pressure was measured directly intraopera-
tively before CPB. Systemic arterial blood pressure was measured
by radial artery catheterization. Patients did not take antioxidant
vitamins (vitamin C and E) or the cyclooxygenase inhibitor indo-
methacin before the operation.
Anesthesia and Surgical Management
Anesthesia was induced with intravenous infusion of midazolam
and fentanyl with muscle relaxant pancuronium, and maintained
with fentanyl (40 g/kg) and bolus midazolam when appropriate.
Patients were ventilated with oxygen FIO2  1.0 during the pro-
cedure. After systemic heparinization, extracorporeal circulation
was instituted at a perfusion flow rate of 2.2 to 2.6 L/m2 per minute
with moderate hypothermia (28°C-26°C of the rectal temperature).
Cardiac asystole was achieved with intermittent multiple-dose cold
St Thomas’ Hospital cardioplegic solution after continuous appli-
cation of the aortic crossclamp. Patients’ hematocrit values were
maintained between 20% and 26% during and after the operation,
with packed red cells and crystalloid or colloid solution to supple-
ment circulating blood volume. Postoperative inotropic support
was defined as the use of dopamine (5 g · kg1 · min1 with
or without concomitant application of epinephrine (0.01-0.02 g ·
kg · min) for a duration of 30 minutes or longer during the first 12
hours postoperatively. The indication for inotrope administration
was a mean radial arterial blood pressure less than 60 mm Hg.
Experimental Protocol
Eligible patients were randomized to 2 groups after anesthesia
induction and before surgery to group A (control  10) or group
B (treatment  10).
The study drug (SMI; 1 g SM per milliliter, Xingang Pharma-
ceutical Company, Shanghai, China) was diluted in 50 mL of
Ringer’s solution immediately before application. Group B pa-
tients received SMI (100 mg/kg bolus then 100 mg/kg continuous
infusion) at 2 time intervals: (1) preischemia, after anesthetic
induction until the initiation of CPB, and (2) ischemia-reperfusion,
at the initiation of rewarming until 30 minutes after aortic
declamping. The total dosage of SM applied to patients in group B
was 400 mg/kg. Patients in group A received equal volumes of
Ringer’s solution placebo.
Blood samples were taken from a central venous cannulation at
7 time points: post-anesthesia induction (T0), 10 minutes (T1) and
30 minutes (T2) after the onset of CPB, 10 minutes (T3) and 30
minutes (T4) after aortic declamping (myocardial reperfusion), and
30 minutes (T5) and 24 hours (T6) after termination of CPB.
Blood samples were collected in duplicate. One part of the
blood samples was processed on the same day for superoxide
dismutase (SOD), lactate dehydrogenase (LDH), and myocardial-
specific creatine kinase (CK)-MB activities and the lipid peroxi-
dation product malondialdehyde (MDA) content. Another part of
the blood samples was immediately centrifuged, and the plasma
was frozen at 70°C and stored until assayed for TXB2, 6-keto-
PGF1 (stable metabolites of TXA2 and PGI2, respectively), and
ET-1.
Figure 1. Chemical structure of salvianolic acid A isolated from
Salvia miltiorrhiza.
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Bioassays
SOD, MDA, LDH, and CK-MB were measured by chemical
analysis (commercial kits; Nanjing Jiangzheng Biological Engine
Institute, Nanjing, China). ET-1, 6-keto-PGF1, and TXB2 were
measured by radioimmunoasay using specific monoclonal antibod-
ies (commercial kits; Thromboxane Research Institute, Shuzhou
Medical College, Shuzhou, China). The samples were coded, and
the investigators were blinded with respect to patient group.
Statistical Analysis
All continuous data were expressed as mean  SEM. Statistical
evaluation of patients’ files and perioperative data was performed
with an unpaired Student t test or 2 test when appropriate.
Between groups and within group differences of bioassay data
were analyzed using 2-way analysis of variance with repeated
measures and Bonferroni’s corrections (GraphPad Prism, Graph-
Pad Software, San Diego, Calif) when appropriate. Correlations
were evaluated with the Pearson test.
Results
Patient Profile and Perioperative Data
Patient demographic and operative data are presented in
Table 1. Patients were similar in terms of age, diagnosis,
preoperative systemic arterial pressure, mean pulmonary
pressure to mean systemic arterial pressure ratio, and dura-
tion of CPB and aortic crossclamping. Six patients in group
A (6/10) needed postoperative inotropic support compared
with 1 patient in group B (1/10) (P  .05). The duration for
inotrope use was 2 hours for the patient in group B. Two
patients in group A needed continued postoperative inotro-
pic support for up to 9 and 20 hours, respectively. There was
no echocardiographic evidence of residual defect in patients
who needed postoperative inotropic support in both groups.
The postoperative duration of mechanical ventilation was
significantly shorter in group B (3.7  0.5 hours, mean 
SEM, range 1.5-5.3 hours) than in group A (6.0  0.8
hours, range 2.5-11 hours) (P  .03). The duration of
postoperative hospital stay did not differ between groups (P
 .05). Most patients were discharged within 2 weeks
postoperatively. One patient in group A was discharged
after 3 weeks because of pulmonary complications.
Plasma Levels of MDA and SOD
Preoperative levels of MDA and SOD (Figure 2) did not
differ between groups. MDA in group A increased signifi-
cantly at 10 minutes after the onset of CPB (T1), continued
to increase, and remained significantly different from MDA
in group B at all time intervals (P  .001). MDA in group
B did not change during CPB and reperfusion. SOD
activity decreased significantly in group A during myo-
cardial ischemia (T2). This decrease did not occur until
10 minutes of reperfusion (T3) in group B. SOD levels in
group B were significantly higher than in group A at 24
hours (T6).
Plasma Levels of LDH and CK-MB Activity
Baseline levels of LDH and CK-MB (Figure 2) did not
differ between groups. The level of LDH in group A in-
creased significantly at 10 minutes after the onset of CPB
(T1) and was significantly higher than LDH in group B
during ischemia (T2) and early reperfusion (T3), and at 24
hours (T6) (P  .05). LDH initially decreased and did not
increase significantly above baseline until 30 minutes of
reperfusion (T4) in group B. CK-MB increased significantly
after reperfusion in both groups and peaked at 30 minutes
after CPB (T5). It was, however, significantly lower in
group B, compared with group A, at T5 (P  .05, Figure 2,
D).
Plasma Levels of 6-Keto-PGF1, TXB2, and Their
Ratio
6-keto-PGF1, TXB2, and their ratio (Figure 3) did not
differ between groups at baseline. 6-keto-PGF1 increased
significantly during CPB in both groups and peaked at 30
minutes during CPB (T2) in group A and at 10 minutes of
reperfusion (T3) in group B. It decreased gradually thereaf-
ter, but 6-keto-PGF1 in group A remained significantly
higher than in group B at 24 hours (T6). In a similar manner,
TXB2 increased during CPB in both groups and peaked at
30 minutes during CPB (T2). TXB2 in group A remained
significantly elevated during reperfusion and returned to
baseline at 24 hours (T6). TXB2 decreased significantly at
30 minutes of reperfusion (T4) and remained below baseline
TABLE 1. Patient profile and perioperative data
Group A
(n  10)
Group B
(n  10)
Age (y)* 8.6 1.3 8.1 1.3
(range) (3–15) (2–15)
Gender (M/F) 7/3 7/3
Weight (kg)* 22.9 2.4 21.9 2.2
Congenital heart defects
(VSD/ASD) 9/1 8/2
Systemic AP (mm Hg)*
Systolic 104.2 2.5 105.2 2.0
Diastolic 69.3 2.8 69.6 2.8
Mean 80.9 2.6 81.5 2.5
Pulmonary AP (mm Hg)*
Systolic 51.6 2.6 53.0 2.9
Diastolic 21.0 1.3 21.5 1.5
Mean 31.2 1.5 32.0 1.6
Pp/Ps ratio* 0.38 0.01 0.39 0.01
CPB time (min)* 75.7 4.2 77.6 4.5
ACC time (min)* 40.7 3.7 45.5 3.9
Post-CPB inotrope
(yes/no) 6/4 1/9†
AP, Arterial pressure; Pp, mean pulmonary pressure; Ps, mean systemic
pressure; CPB, cardiopulmonary bypass; ACC, aortic crossclamping; VSD,
ventricular septal defect; ASD, atrial septal defect.
*Mean  SEM.
†P  .05 vs group A (2 test).
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for up to 24 hours (T6) in group B (P .05). TXB2 in group
B was significantly lower than TXB2 in group A at T5 and
T6. The 6-keto-PGF1/TXB2 ratio increased significantly at
T2, T3, and T4 in group A and returned to baseline levels
thereafter. The 6-keto-PGF1/TXB2 ratio in group B was
significantly higher than in group A at T1 and T5 (P 
.05).
Plasma Levels of ET-1
ET-1 decreased significantly during CPB at 10 minutes (T1)
in both groups (Figure 3, D). ET-1 increased significantly
after 30 minutes of reperfusion (T4) and peaked at T5 in
group A. ET-1 in group B remained significantly lower at 30
Figure 2. A-D, Variations of perioperative plasma levels of mal-
ondialdehyde (MDA) content, superoxide dismutase (SOD), lac-
tate dehydrogenase (LDH), and creatine kinase (CK)-MB activi-
ties. The time points 0, 1, 2, 3, 4, 5, and 6 represent baseline (T0),
10 (T1) and 30 (T2) minutes after the onset of CBP, 10 (T3) and 30
(T4) minutes of reperfusion, 30 minutes after stopping CPB (T5),
and 24 hours (T6) after operation, respectively. (*P < .05 vs
baseline; P < .05 vs group B.)
Figure 3. A-D, Variations of perioperative plasma levels of 6-ke-
to-prostaglandin (PG)F1, thromboxane (TX) B2, ratio of 6-keto-
PGF1 over TXB2, and endothelin (ET)-1. The time points 0, 1, 2, 3,
4, 5, and 6 represent baseline (T0), 10 (T1) and 30 (T2) minutes after
the onset of CPB, 10 (T3) and 30 (T4) minutes of reperfusion, 30
minutes after stopping CPB (T5), and 24 hours (T6) after operation,
respectively. (*P < .05 vs baseline;P < .05 vs group B; #P < .05
vs T2.)
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minutes of reperfusion (T5) and 24 hours (T6), compared
with group A (P  .05).
Correlation Analysis
Plasma MDA was significantly correlated with CK-MB at
30 minutes after the completion of CPB (CK-MB; r 0.71,
P  .0005, Figure 4). Figure 5 depicts the significant
negative correlation between the 6-keto-PGF1/TXB2 ratio
and ET-1 24 hours after operation (r  0.64, P  .0025).
Discussion
Our study is the first to investigate the effects of a novel
antioxidant therapy on the relationship of systemic lipid
peroxidation to plasma levels of ET-1 and the PGI2/TXA2
ratio after cardiac surgery in patients with congenital heart
disease and pulmonary hypertension. The major findings
include the following: (1) The level of systemic lipid per-
oxidation after CPB is significantly correlated with myocar-
dial damage as evidenced by myocardial specific CK-MB,
(2) antioxidant therapy results in increased postoperative
hemodynamic stability, and (3) the postoperative plasma
level of ET-1 is highly negatively correlated with the PGI2/
TXA2 ratio.
Host antioxidants become depleted after CPB.19 Cellular
injury occurs as the result of lipid peroxidation when the
production of reactive OFRs exceeds host-defense scaveng-
ing capacity.20 A study has shown that the lipid peroxide
concentration in patients undergoing coronary artery bypass
grafting with CPB is correlated with the release of cardiac
troponin T, a specific marker of myocyte damage, 90 min-
utes after CPB.19 This is similar to our finding that lipid
peroxidation at 30 minutes after CPB is significantly corre-
lated with myocardial damage (CK-MB) in this pediatric
cardiac population.
SM has demonstrated beneficial effects on ischemic dis-
eases21 and contains several phenolic compounds (eg, salvi-
anolic acids A and B, and danshensu).18 Salvianolic acid A
(Figure 1) is the main OFR scavenger.18,22 A study using
the electron spin resonance trapping technique has found
that SM can directly scavenge OFRs generated from the
reaction system of xanthine and xanthine oxidase17 and
protect myocardial mitochondrial membrane from isch-
emia-reperfusion injury. Treatment with SM in our study
prevented the increase of MDA seen in controls during and
after CPB. LDH levels decreased significantly at 10 minutes
after the onset of CPB (T1), and the 6-keto-PGF1/TXB2
ratio increased significantly at the beginning of CPB in
group B. The inability of SM to completely prevent an
increase in cardiac enzymes likely reflects a multifactorial
cause of postoperative myocardial injury not solely related
to OFR generation. An alternative explanation could be that
antioxidants, such as the well-known antioxidant vitamins C
and E, might be unable to prevent OFR production by other
sources despite the inhibition of OFR release from activated
polymorphonucleated cells, as recently reported by Wagner
and colleagues.23 This is, however, not likely the case with
SM, which completely prevented the increase of lipid per-
oxidation in plasma (Figure 2, A). This is different from the
effects of vitamins C and E, which failed to significantly
prevent the increase in OFR release in the whole blood
during pulmonary reperfusion.23 Our results are in keeping
with the protective effects of antioxidant therapy on myo-
cardial ischemia-reperfusion injury seen in previous clinical
and laboratory studies.24,25 We conclude that SM acts
through its OFR scavenger properties.
We measured higher baseline values of ET-1 than did
Komai and colleagues.7 This discrepancy cannot be com-
pletely explained by variation in specificity of the monoclo-
nal antibodies used in each study, despite the fact that ET-1
concentrations detected in the plasma of healthy subjects by
different researchers may vary between 0.1 and 48 fmol/mL
(0.25-120 pg/mL).26 It may reflect patient differences with
respect to age or ethnic origin. The mean age of the patients
in Komai’s study was 1.6 years. The patients we studied
Figure 4. Correlation between plasma MDA and CK-MB activity
and ET-1 at 30 minutes post-CPB. Significant correlation exists
between MDA and CK-MB (r  0.7074, 95% confidence interval:
0.3855-0.8758, P  .0005) 30 minutes after completion of CPB.
Figure 5. Postoperatively (24 hours), logarithmic plasma ET-1
concentration (log pg/mL) was significantly negatively correlated
with the ratio of 6-keto-PGF1 over TXB2 (r  0.6373, 95%
confidence interval 0.8423-0.2711, P  .0025).
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were older. We did measure baseline ET-1 values of 19.5
and 28.2 pg/mL in 2- and 3-year-old patients, respectively.
This is comparable to the results of Yoshibayashi and col-
leagues.27 It is possible that ET-1 levels increase as patients
with congenital heart defects grow older.
We found that ET-1 significantly increased 30 minutes
after terminating CPB. This result is similar to that found by
Komai and coworkers,7 who observed a significant increase
of ET-1 20 minutes after termination of CPB. The finding of
a significant decrease in ET-1 during CPB until 10 minutes
of reperfusion in our control group is distinct from the work
of Komai and colleagues. The precise mechanism for this
decrease in ET-1 is uncertain. Hemodilution is an unlikely
cause. It may be explained, in part, by Komai and col-
leagues’ use of arterial blood, compared with the central
venous blood sampling performed in our study. A differ-
ence in arterial and venous ET-1 levels exists during and,
particularly, after CPB.7
The increase in PGI2 and TXA2 during CPB that we
observed is in keeping with Greeley and colleagues’
study.16 We identified a tight inverse correlation between
the ratio of PGI2/TXA2 and ET-1 concentration 24 hours
postoperatively. The precise mechanism is uncertain. Ex-
perimental study has shown that PGI2 can inhibit the pro-
duction and secretion of ET from the cultured endothelial
cells,28 likely by stimulating particulate guanylate cyclase.29
However, we did not find a significant correlation between
PGI2 and ET-1 postoperatively. This may indicate that the
balance between PGI2 and TXA2 is more important than
PGI2 alone in regulating ET-1 in this clinical setting.
Treatment with SM significantly inhibited the increase of
TXA2 and enhanced the ratio of PGI2/TXA2 after CPB.
This increase in the PGI2/TXA2 ratio seems clinically im-
portant because it relates to differences in the inotrope
requirements between groups. The endothelium-derived re-
laxing factor NO and PGI2 are believed to oppose the
vasoconstrictor action of ET-1 and TXA2. However, plasma
levels of NO have been shown to not change, whereas ET-1
significantly increased after CPB in similar patients.6 Thus,
the increase in the PGI2/TXA2 ratio becomes an important
factor opposing the effects of ET-1 after CPB in this clinical
setting.
Adatia and colleagues showed30 that the urinary excre-
tion of TXA2 metabolites over PGI2 metabolites was higher
in children with a left to right shunt and pulmonary hyper-
tension preoperatively compared with healthy age-matched
subjects. The urinary TXA2/PGI2 ratio significantly de-
creased 12 to 24 hours after successful intracardiac repair
and was comparable to the TXA2/PGI2 ratio in the control
subjects.30 The plasma PGI2/TXA2 ratio increased from
0.46  0.06 before operation to 0.66  0.07 at 24 hours
after successful intracardiac repair in group A in our study
(Figure 3, C), which is similar to the finding of Adatia and
colleagues.13 Our study extends their finding. We observed
that the plasma PGI2/TXA2 ratio tends to decrease tempo-
rarily during the early phase of reperfusion in the untreated
group (group A). SM treatment increased and consistently
maintained the plasma PGI2/TXA2 ratio at a relatively
higher level. This is of significance, because postoperative
myocardial dysfunction occurs primarily during the first
several hours after myocardial ischemia and reperfusion.
Conclusion
We studied 20 pediatric patients with preoperative pulmo-
nary hypertension during surgical correction of congenital
heart defects. Antioxidant therapy with SM proved useful in
reducing the ET-1 response and was associated with in-
creased postoperative hemodynamic stability. On the basis
of our findings, we conclude that an increase in PGI2 or the
PGI2/TXA2 ratio influences this process. The latter may
inhibit the secretion of ET-1.28,29
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